Patents by Inventor Edda Spiekerkoetter

Edda Spiekerkoetter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF FK506 FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
    Publication number: 20230404982
    Abstract: A method for reducing pulmonary hypertension in a mammal that employs FK506 is provided. In certain embodiments, the method comprises administering FK506 to a mammal having pulmonary arterial hypertension associated with defective MBPR2 signaling at a dosage sufficient to reduce blood pressure in the pulmonary artery of the mammal.
    Type: Application
    Filed: January 6, 2023
    Publication date: December 21, 2023
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Edda SPIEKERKOETTER, Marlene RABINOVITCH, Philip A. BEACHY, David SOLOW-CORDERO
  • Enzastaurin and fragile histidine triad (FHIT)-increasing agents for the treatment of pulmonary hypertension
    Patent number: 11413280
    Abstract: The present invention provides methods for treatment or prevention of pulmonary hypertension and emphysema using agents that increase activity of FHIT, such as Enzastaurin. Included are methods for using levels of FHIT and/or BMPR2, and checking for mutations in FHIT and/or BMPR2, to select patients for treatment or to monitor effectiveness of treatment. The invention is based on evidence that Enzastaurin prevents and reverses pulmonary hypertension induced in animal model systems, and that it acts by up-regulation of FHIT and/or BMPR2.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: August 16, 2022
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Edda Spiekerkoetter, Svenja Dannewitz Prosseda, Xuefei Tian, Purvesh Khatri
  • FK506 FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
    Publication number: 20220184042
    Abstract: A method for reducing pulmonary hypertension in a mammal that employs FK506 is provided. In certain embodiments, the method comprises administering FK506 to a mammal having pulmonary arterial hypertension associated with defective MBPR2 signaling at a dosage sufficient to reduce blood pressure in the pulmonary artery of the mammal.
    Type: Application
    Filed: July 29, 2020
    Publication date: June 16, 2022
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Edda SPIEKERKOETTER, Marlene RABINOVITCH, Philip A. BEACHY, David SOLOW-CORDERO
  • ENZASTAURIN AND FRAGILE HISTIDINE TRIAD (FHIT)-INCREASING AGENTS FOR THE TREATMENT OF PULMONARY HYPERTENSION
    Publication number: 20200206214
    Abstract: The present invention provides methods for treatment or prevention of pulmonary hypertension and emphysema using agents that increase activity of FHIT, such as Enzastaurin. Included are methods for using levels of FHIT and/or BMPR2, and checking for mutations in FHIT and/or BMPR2, to select patients for treatment or to monitor effectiveness of treatment. The invention is based on evidence that Enzastaurin prevents and reverses pulmonary hypertension induced in animal model systems, and that it acts by up-regulation of FHIT and/or BMPR2.
    Type: Application
    Filed: May 18, 2018
    Publication date: July 2, 2020
    Inventors: Edda SPIEKERKOETTER, Svenja DANNEWITZ PROSSEDA, Xuefei TIAN, Purvesh KHATRI
  • USE OF FK506 FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
    Publication number: 20190091208
    Abstract: A method for reducing pulmonary hypertension in a mammal that employs FK506 is provided. In certain embodiments, the method comprises administering FK506 to a mammal having pulmonary arterial hypertension associated with defective MBPR2 signaling at a dosage sufficient to reduce blood pressure in the pulmonary artery of the mammal.
    Type: Application
    Filed: November 21, 2018
    Publication date: March 28, 2019
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Edda SPIEKERKOETTER, Marlene Rabinovitch, Phillip A. Beachy, David Solow-Cordero
  • USE OF FK506 FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
    Publication number: 20180185340
    Abstract: A method for reducing pulmonary hypertension in a mammal that employs FK506 is provided. In certain embodiments, the method comprises administering FK506 to a mammal having pulmonary arterial hypertension associated with defective MBPR2 signaling at a dosage sufficient to reduce blood pressure in the pulmonary artery of the mammal.
    Type: Application
    Filed: October 12, 2017
    Publication date: July 5, 2018
    Inventors: Edda SPIEKERKOETTER, Marlene RABINOVITCH, Phillip A. BEACHY, David SOLOW-CORDERO
  • USE OF FK506 FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
    Publication number: 20170007585
    Abstract: A method for reducing pulmonary hypertension in a mammal that employs FK506 is provided. In certain embodiments, the method comprises administering FK506 to a mammal having pulmonary arterial hypertension associated with defective MBPR2 signaling at a dosage sufficient to reduce blood pressure in the pulmonary artery of the mammal.
    Type: Application
    Filed: September 21, 2016
    Publication date: January 12, 2017
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Edda SPIEKERKOETTER, Marlene RABINOVITCH, Phillip A. BEACHY, David SOLOW-CORDERO
  • Use of FK506 for the treatment of pulmonary arterial hypertension
    Patent number: 9474745
    Abstract: A method of reducing pulmonary arterial hypertension in a mammal that employs FK506 is provided. In certain embodiments, the method comprises administering FK506 to a mammal having pulmonary arterial hypertension associated with defective MBPR2 signaling at a dosage sufficient to reduce blood pressure in the pulmonary artery of the mammal.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: October 25, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Edda Spiekerkoetter, Marlene Rabinovitch, Philip A. Beachy, David Solow-Cordero
  • Use of FK506 for the Treatment of Pulmonary Arterial Hypertension
    Publication number: 20140135358
    Abstract: A method of reducing pulmonary arterial hypertension in a mammal that employs FK506 is provided. In certain embodiments, the method comprises administering FK506 to a mammal having pulmonary arterial hypertension associated with defective MBPR2 signaling at a dosage sufficient to reduce blood pressure in the pulmonary artery of the mammal.
    Type: Application
    Filed: April 30, 2012
    Publication date: May 15, 2014
    Inventors: Edda Spiekerkoetter, Marlene Rabinovitch, Philip A. Beachy, David Solow-Cordero